Dihexa: an angiotensin IV analogue that shrugs off proteases

Dihexa is not really a peptide in the ordinary sense, and that is the first thing to understand about it. It is an N-acylated dipeptide analogue derived from angiotensin IV, with the structure N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide. Two natural-looking residues sit in the middle, wrapped on both sides by synthetic modifications: a fatty hexanoyl group at one end and an aminohexanoic amide at the other. Those caps are what make it a peptidomimetic, a molecule engineered to survive in tissue where a plain peptide would be cut apart within minutes and to cross the blood-brain barrier that keeps most peptides out of the central nervous system. Because of that design it has no conventional amino-acid sequence to display and is described by its chemical structure instead.

The compound came out of the laboratory of Joseph Harding and John Wright at Washington State University, part of a long effort to turn angiotensin IV into something stable enough to study in the brain. Angiotensin IV is a short fragment of the angiotensin peptide family that earlier research had linked to memory and learning, but like most small peptides it is broken down almost immediately in tissue, which made it nearly impossible to work with in living systems. Dihexa was engineered as a metabolically stabilised analogue that keeps the procognitive character attributed to angiotensin IV while resisting the enzymes that destroy the parent. The hexanoyl cap in particular makes it far more lipophilic, and lipophilicity is the property that lets a molecule slip through the barrier surrounding the brain.

The most-cited mechanistic claim is that Dihexa acts on hepatocyte growth factor (HGF) and its receptor c-Met. In this model the molecule behaves as a potentiator: it is reported to bind HGF and amplify its signalling, which in turn is said to drive synaptogenesis, the formation of new synaptic connections between neurons. Cell-culture work has described increases in synapse number and dendritic activity when hippocampal neurons are exposed to the compound, and rodent models of cognitive impairment used behavioural performance as a readout to probe whether that synaptogenic activity translates into function. The HGF/c-Met framing is what separates Dihexa from the older angiotensin-IV story, which had been built around the AT4 receptor (also known as insulin-regulated aminopeptidase). Which of these targets actually matters is not fully resolved.

The research record is compact and largely produced by a small circle of investigators. It covers binding and potency measurements benchmarked against angiotensin IV, in-vitro synaptogenesis assays in cultured hippocampal neurons, and rodent models of memory deficit in which behavioural performance served as the endpoint. Interest has concentrated on neurodegeneration and cognition, which is why the molecule is frequently described in the literature as a procognitive or antidementia research compound. A separate and important strand probes the exact molecular partner, because the HGF/c-Met claim, central as it is, has not gone unchallenged. When a compound's headline mechanism and its main functional data both originate largely with the same group, independent scrutiny of that mechanism becomes the interesting part of the story.

Because Dihexa is a modified dipeptide carrying non-standard groups on both ends, it has no meaningful amino-acid sequence to write out, and it is represented by its chemical structure rather than a residue chain. Its verified molecular formula, mass and CAS number are listed below and are what allow the material to be identified unambiguously. The hexanoyl cap also makes the molecule markedly more lipophilic than a typical peptide, and that single property does a lot of work in the story: it is the basis for the claim that the compound can reach the central nervous system at all, and it distinguishes Dihexa sharply from the water-soluble parent fragment it was derived from. Small structural changes, large behavioural consequences, at least on paper.

Skepticism is warranted on two fronts. First, the evidence base is small and concentrated: much of it originates with the group that invented the molecule, and large independent replication is scarce. Second, the headline mechanism is contested. At least one report has questioned whether Dihexa binds c-Met directly at the potencies claimed, and that matters because the entire synaptogenesis narrative hangs on that specific interaction. If the binding is weaker or indirect, the mechanistic account needs rewriting even if the behavioural observations hold up. The fair summary is that Dihexa is genuinely interesting as a stabilised angiotensin-IV analogue and as a chemical probe of memory-related signalling, but the confidence of the mechanistic claims currently outruns the volume of independent data standing behind them.

For laboratory research use only. Not for human or veterinary use.

Verified molecule

• Structure: N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide (angiotensin IV analogue; no standard residue sequence)
• Molecular formula: C27H44N4O5
• Molecular weight: 504.7 g/mol
• CAS number: 1401708-83-5

Common questions

Why does Dihexa have no amino-acid sequence?

It is a peptidomimetic, not a standard peptide. Only two residues sit in the middle of the molecule, and both ends carry synthetic groups: a hexanoyl cap on one side and an aminohexanoic amide on the other. There is no ordinary chain of standard residues to spell out, so the compound is defined by its chemical structure and its verified formula rather than by a sequence graphic.

What is the HGF/c-Met connection?

The leading hypothesis is that Dihexa binds hepatocyte growth factor and enhances signalling through its receptor c-Met, a pathway linked to the growth of new synapses in cell studies. This idea is influential and drives most of the interest in the molecule, but it has been questioned in the literature, so it is best read as an active area of investigation rather than an established fact.

How does it relate to angiotensin IV?

Dihexa was engineered from angiotensin IV, a short peptide tied in earlier work to memory-related signalling but destroyed almost instantly in tissue. The synthetic caps make Dihexa far more stable and far more lipophilic, which is why it became a workable research tool where the fragile parent fragment was not. In that sense Dihexa is angiotensin IV reworked for durability and brain access.

References

1. McCoy AT, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics, 2013.
2. Benoist CC, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics, 2014.